 I. To determine the objective response rate ORR of pembrolizumab combined with cryoablation and intratumoral mature dendritic cells mDCs in patients with metastatic melanoma that has failed to respond or has stopped responding to initial therapy with a PD-1 axis-blocking monoclonal antibody. 